AP PHOTOS: More than 200 Ukrainian POWs have died in Russian prisons. This is one soldier's story
Kyiv, Ukraine (AP) — 'Everything will be all right.'
Ukrainian soldier Serhii Hryhoriev said this so often during brief phone calls from the front that his wife and two daughters took it to heart. His younger daughter, Oksana, tattooed the phrase on her wrist as a talisman.
Even after Hryhoriev was captured by the Russian army in 2022, his anxious family clung to the belief that he would ultimately be OK. After all, Russia is bound by international law to protect prisoners of war.
When Hryhoriev finally came home, though, it was in a body bag.
A Russian death certificate said the 59-year-old died of a stroke. But a Ukrainian autopsy and a former POW who was detained with him tell a different story about how he died – one of violence and medical neglect at the hands of his captors.
Hryhoriev is one of more than 200 Ukrainian POWs who have died while imprisoned since Russia's full-scale invasion three years ago. Abuse inside Russian prisons was likely a contributing factor in many of these deaths, according to officials from human rights groups, the U.N., the Ukrainian government and a Ukrainian medical examiner who has performed dozens of POW autopsies.
-
This is a photo gallery curated by AP photo editors.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
24 minutes ago
- Bloomberg
EU Poised to Curb China's Access to Medical Device Procurement
The European Union is set to curb Chinese medical device manufacturers' access to public procurement contracts in the bloc, according to a person familiar with the matter. EU countries are due to vote on the proposed measure as early as Monday, said the person, who spoke on condition of anonymity to discuss private deliberations.
Associated Press
an hour ago
- Associated Press
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS). The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatment of SBS is based on results from a pivotal Phase 3 trial (EASE-1), supported by interim results from two ongoing long-term extension trials (EASE-2 and EASE-3) and results from a mechanistic trial (EASE-4). 'We are pleased to bring our potential best-in-class GLP-2 analog, glepaglutide, one step closer to patients in Europe living with short bowel syndrome with intestinal failure, who urgently need more effective and more convenient treatment options,' said David Kendall, MD, Chief Medical Officer of Zealand Pharma. 'We believe that glepaglutide, administered twice weekly, offers meaningful potential to reduce both the burden of parenteral support and the inconvenience of daily dosing required with the only currently available GLP-2 therapy. Looking ahead, we expect to initiate the EASE-5 Phase 3 trial in the second half of the year to obtain further confirmatory safety and efficacy data on the twice weekly dosing regimen, supporting regulatory submission in the U.S.' About glepaglutide Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is developed as a liquid product in an autoinjector designed for subcutaneous administration by twice weekly dosing, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for glepaglutide for the treatment of SBS. About the EASE Clinical Trial Program The Phase 3 program, named EASE, is designed to evaluate the potential for glepaglutide to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure. EASE-1 (NCT03690206) was a randomized, double-blind Phase 3 trial that enrolled a total of 106 SBS patients with intestinal failure who were dependent on parenteral support for at least three days per week. Patients were evenly randomized to receive treatment with 10 mg glepaglutide administered either once or twice weekly, or placebo. The primary endpoint in the trial was the absolute change in weekly parenteral support volume from baseline at 24 weeks. At 24 weeks, glepaglutide administered twice weekly significantly reduced the total weekly volume of PS by 5.13 liters/week, compared to a reduction of 2.85 liters/week in the placebo group (p=0.0039). When administered once weekly, glepaglutide treatment resulted in a reduction in weekly PS of 3.13 liters/week, however this did not achieve statistical significance. A total of 9 patients treated with glepaglutide were completely weaned off PS (achieving enteral autonomy), while no placebo-treated patients were able to discontinue PS. For patients treated with glepaglutide twice weekly, 14% of patients (n=5) achieved enteral autonomy. In total, 102 of 106 participating patients completed EASE-1, of which 96 continued into the ongoing two-year, long-term safety and efficacy extension trial, EASE-2. EASE-2 (NCT03905707) is a randomized, double-blind trial in which SBS patients continued their randomly assigned treatment from EASE-1 with glepaglutide 10 mg once- or twice-weekly. Patients who received placebo in EASE-1 were re-randomized to treatment with either glepaglutide 10 mg once- or twice-weekly. In an interim analysis conducted after at least six months of treatment, clinical response to glepaglutide across the key efficacy endpoints was generally maintained or showed continued improvement, including additional patients on both doses weaning off PS. Patients who complete EASE-2 are eligible to participate in EASE-3 (NCT04881825), evaluating glepaglutide administered once weekly using an autoinjector. An interim analysis of EASE-3, conducted with the first 57 patients rolled over from EASE 2, showed that the reduction in prescribed PS was generally maintained. EASE-4 (NCT04991311) was a Phase 3b trial to assess mechanistic effects of glepaglutide on intestinal fluid and energy uptake. The trial provides evidence of the pharmacodynamic effects of glepaglutide in improving intestinal absorption. In the second half of 2025, Zealand Pharma expects to initiate EASE-5, a single Phase 3 clinical trial that is anticipated to provide further confirmatory evidence for a regulatory submission in the U.S. About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ('Zealand') is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit Forward looking statements This press release contains 'forward-looking statements', as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company's pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would' and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. Contacts Adam Lange (Investors) Vice President, Investor Relations [email protected] Neshat Ahmadi (Investors) Investor Relations Manager [email protected] Anna Krassowska, PhD (Investors and Media) Vice President, Investor Relations & Corporate Communications [email protected]
Yahoo
an hour ago
- Yahoo
Ukraine and Russia meet in Turkey for peace talks with few hopes for a breakthrough
ISTANBUL (AP) — Delegations from Russia and Ukraine gathered in Turkey on Monday for their second round of direct peace talks in just over two weeks, although expectations were low for any significant progress on ending the three-year war. The Ukrainian delegation led Defense Minister Rustem Umerov was in Istanbul for the meeting, according to Heorhii Tykhyi, spokesperson for the Ukrainian Foreign Ministry, said in a message posted on the Ukrainian Embassy Whatsapp group. The Russian delegation headed by Vladimir Medinsky, an aide to Russian leader Vladimir Putin, arrived Sunday evening, Russian state media reported. Turkish officials said the meeting would start at 1 p.m. local time, with Turkish Foreign Minister Hakan Fidan presiding over the talks and officials from the Turkish intelligence agency also present. However, Ukrainian spokesperson Tykhyi said the start would be at midday local time. It was not immediately possible to clarify the discrepancy. Recent comments by senior officials in both countries indicate they remain far apart on the key conditions for stopping the war. Fierce fighting has in the meantime continued along the roughly 1,000-kilometer (620-mile) front line, and both sides have hit each other's territory with deep strikes. On Sunday, a Ukrainian drone attack destroyed more than 40 Russian planes deep inside Russia, Ukraine's Security Service said, while Moscow pounded Ukraine with missiles and drones. Russian air defenses downed 162 Ukrainian drones over eight Russian regions overnight, as well as over the annexed Ukrainian peninsula of Crimea, Russia's Defense Ministry said Monday. Ukrainian air defenses damaged 52 out of 80 drones launched by Russia overnight, the Ukrainian air force said. Two ballistic missiles struck a residential neighborhood in the northeastern Ukrainian city of Kharkiv on Monday morning, including one that hit near a school, the city's mayor said. One missile landed near an apartment building, while the second struck a road near the school, Kharkiv Mayor Ihor Terekhov said in a statement and published a photo of a wide crater. 'Standing next to the crater, you realize how different it all could have been,' Terekhov wrote. 'A few more meters — and it would have hit the building. A few more minutes — and cars, buses would have been on the road.' No casualties were reported. ___ Suzan Frazer in Ankara, Turkey, and Hanna Arhirova in Kyiv, Ukraine, contributed to this report. ___ Follow AP's coverage of the war in Ukraine at Mehmet Guzel, The Associated Press
